Results 101 to 110 of about 1,829,207 (256)

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

Functional Adaptation in the Brain Habenulo–Mesencephalic Pathway During Cannabinoid Withdrawal

Cells
The mesolimbic reward system originating from dopamine neurons in the ventral tegmental area (VTA) of the midbrain shows a profound reduction in function during cannabinoid withdrawal.
Sonia Aroni, Claudia Sagheddu, Marco Pistis, Anna Lisa Muntoni   +3 more
doaj   +1 more source

Scores of the symptoms of morphine withdrawal syndrome.

, 2016
Scores of the symptoms of morphine withdrawal syndrome.
Renyu Liu (184348), Fei-xiang Wu (380843), Yan He (116705), Hui-ting Di (2579446), Wei-feng Yu (196134), Rui-rui Pan (2579449), Yu-ming Sun (2579443)   +6 more
core   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

The alcohol withdrawal syndrome.

, 2008
The alcohol withdrawal syndrome (AWS) is a common management problem in hospital practice for neurologists, psychiatrists and general physicians alike.
Delanty, Norman, Frye, M A, McKeon, A
core   +1 more source

Ethanol-conditioned withdrawal syndrome [PDF]

, 2002
The withdrawal syndrome is closely related to the concepts of tolerance and physical dependence. The chronic consumption of a drug is believed to induce adaptive changes that are designed to oppose the acute effects of the drug.
De Witte, Philippe, Quertemont, Etienne
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Causality assessment tool for drug‐induced acute kidney injury in patients admitted to intensive care units: Requirements from a multicentre retrospective study in the Netherlands reusing data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to provide key requirements for a drug‐induced acute kidney injury (d‐AKI) causality assessment tool (CAT) for intensive care unit (ICU) patients, using vancomycin‐induced AKI (v‐AKI) as a test case. Methods A retrospective review was conducted by medical experts of electronic health records of ICU patients from 14 Dutch ICUs.
Joanna E. Klopotowska, Izak A. R. Yasrebi‐de Kom, Nicolette F. de Keizer, Dave A. Dongelmans, on behalf of the RESCUE Study group, Merijn C. Reuland, Irma M. Rigter, Peter F. Schutte, Ilona T. Spaan, Dorieke van Balen, Stefaan Hendriks, Petronella E. Deetman, Cedric Lau, Wytze J. Vermeijden, Marieke G. J. Schouten, Joost B. Masselink, Peter E. Spronk, Marnix Kuindersma, Hendrikus J. M. van Kan, Anne Wellink, Abraham J. Valkenburg, Andre Wieringa, Walter M. van den Bergh, Maurits H. Renes, Wouter Bult, Frouke M. Engelaer, Nienke van Rein, Martijn Hoeksema, Janneke M. van den Broek, Elsbeth Wesselink, Ilse M. Purmer, Thomas Ottens, Bertha E. Bosma, Sjoerd H. W. van Bree, Barbara Festen, Hendrick J. W. Lammers, Rob J. Bosman, Rogier M. Determann, Eric J. F. Franssen, Attila Karakus, Lenneke. E. M. Haas, Freek van Gorp, Dylan W. de Lange, Maaike A. Sikma, Esther V. Uijtendaal   +44 more
wiley   +1 more source